ROCKET PHARMACEUTICALS, INC. - Common stock, $0.01 par value per share (RCKT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Type / Class
Equity / Common stock, $0.01 par value per share
Symbol
RCKT on Nasdaq
Shares outstanding
109,265,652
Price per share
$3.71
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
91,155,670
Total reported value
$319,980,752
% of total 13F portfolios
0%
Share change
-5,149,008
Value change
-$17,976,922
Number of holders
179
Price from insider filings
$3.71
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ROCKET PHARMACEUTICALS, INC. - Common stock, $0.01 par value per share (RCKT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 7.9% $29,992,634 8,544,423 The Vanguard Group 31 Dec 2025
MAVERICK CAPITAL LTD 2.3% -69% $9,549,818 -$22,232,671 2,513,110 -70% Maverick Capital, Ltd. 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 0.9% -83% $7,895,181 -$48,317,346 1,004,476 -86% Wellington Management Group LLP 30 May 2025

As of 31 Dec 2025, 179 institutional investors reported holding 91,155,670 shares of ROCKET PHARMACEUTICALS, INC. - Common stock, $0.01 par value per share (RCKT). This represents 83% of the company’s total 109,265,652 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ROCKET PHARMACEUTICALS, INC. - Common stock, $0.01 par value per share (RCKT) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 16% 17,687,772 0% 0.62% $62,084,080
VANGUARD GROUP INC 7.8% 8,544,423 +24% 0% $29,990,925
BlackRock, Inc. 7.2% 7,906,071 +11% 0% $27,750,309
CITIGROUP INC 4.8% 5,246,349 +50225% 0.01% $18,414,685
MORGAN STANLEY 3.6% 3,941,377 +8.1% 0% $13,834,233
SUVRETTA CAPITAL MANAGEMENT, LLC 2.7% 2,992,735 -22% 0.26% $10,504,500
Monaco Asset Management SAM 2.7% 2,987,296 +3.3% 3.1% $10,485,409
Newtyn Management, LLC 2.4% 2,650,000 +5.9% 0.98% $9,301,500
D. E. Shaw & Co., Inc. 2.4% 2,640,518 +21% 0.01% $9,268,218
MAVERICK CAPITAL LTD 2.3% 2,513,110 -70% 0.09% $8,821,016
TWO SIGMA INVESTMENTS, LP 2% 2,131,929 +32% 0.01% $7,483,071
GEODE CAPITAL MANAGEMENT, LLC 1.9% 2,120,269 +11% 0% $7,443,495
TWO SIGMA ADVISERS, LP 1.7% 1,864,651 +3.8% 0.01% $6,544,925
MILLENNIUM MANAGEMENT LLC 1.6% 1,784,921 -50% 0% $6,265,073
STATE STREET CORP 1.6% 1,700,631 -2.6% 0% $5,969,215
MPM BIOIMPACT LLC 1.5% 1,586,076 -59% 0.64% $5,567,127
JPMORGAN CHASE & CO 1.4% 1,475,624 -30% 0% $5,179,442
CITADEL ADVISORS LLC 1.2% 1,299,991 -22% 0% $4,562,968
Opaleye Management Inc. 0.87% 955,000 0.45% $3,352,050
PRICE T ROWE ASSOCIATES INC /MD/ 0.86% 944,873 -11% 0% $3,318,000
GOLDMAN SACHS GROUP INC 0.86% 936,594 -26% 0% $3,287,444
FEDERATED HERMES, INC. 0.81% 881,249 +40% 0.01% $3,093,184
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.68% 744,286 +0.03% 0% $2,612,444
Prosight Management, LP 0.68% 743,942 -41% 0.54% $2,611,236
AQR CAPITAL MANAGEMENT LLC 0.64% 703,528 -19% 0% $2,469,383

Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common stock, $0.01 par value per share (RCKT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 91,155,670 $319,980,752 -$17,976,922 $3.51 179
2025 Q3 96,588,463 $314,789,902 +$10,419,209 $3.26 171
2025 Q2 94,974,795 $232,855,173 -$147,581,517 $2.45 194
2025 Q1 107,749,040 $722,024,357 -$52,696,378 $6.67 233
2024 Q4 109,632,268 $1,377,359,505 +$161,902,372 $12.57 222
2024 Q3 92,703,462 $1,709,382,927 +$19,027,944 $18.47 189
2024 Q2 91,217,786 $1,963,307,213 -$33,485,873 $21.53 176
2024 Q1 92,048,164 $2,479,705,726 +$111,013,838 $26.94 183
2023 Q4 89,005,050 $2,667,733,521 -$7,076,901 $29.97 192
2023 Q3 89,401,055 $1,831,770,744 +$255,347,743 $20.49 174
2023 Q2 76,338,609 $1,516,884,469 -$31,879,301 $19.87 162
2023 Q1 78,264,099 $1,340,378,412 +$44,795,861 $17.13 161
2022 Q4 75,910,257 $1,486,203,005 +$147,925,718 $19.57 167
2022 Q3 69,117,168 $1,101,781,707 +$65,989,396 $15.96 159
2022 Q2 64,545,073 $887,423,123 +$4,039,525 $13.76 141
2022 Q1 64,321,676 $1,019,794,471 +$10,531,491 $15.86 142
2021 Q4 63,097,635 $1,377,944,582 +$9,053,118 $21.83 141
2021 Q3 61,977,765 $1,849,734,470 -$24,640,220 $29.89 142
2021 Q2 61,808,292 $2,736,555,111 -$11,025,172 $44.29 144
2021 Q1 62,013,212 $2,752,442,865 -$22,930,130 $44.37 169
2020 Q4 61,952,909 $3,397,683,589 +$431,615,785 $54.84 172
2020 Q3 55,227,508 $1,262,686,245 +$19,995,693 $22.86 124
2020 Q2 53,342,815 $1,116,479,207 +$14,452,216 $20.93 113
2020 Q1 53,304,185 $743,593,762 +$12,202,337 $13.95 102
2019 Q4 51,691,134 $1,176,484,498 +$87,809,919 $22.76 116
2019 Q3 47,699,668 $554,996,335 -$32,553,222 $11.65 91
2019 Q2 49,065,584 $735,942,854 +$92,556,483 $15.00 96
2019 Q1 42,874,596 $750,971,351 +$16,305,705 $17.54 80
2018 Q4 42,105,260 $622,102,055 +$68,806,707 $14.82 86
2018 Q3 36,793,895 $905,863,120 +$70,641,682 $24.62 82
2018 Q2 31,064,522 $605,382,076 +$63,867,898 $19.63 75
2018 Q1 27,976,061 $502,091,019 +$502,091,019 $18.75 55